Kopran Ltd
Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.
- Market Cap ₹ 996 Cr.
- Current Price ₹ 206
- High / Low ₹ 219 / 107
- Stock P/E 32.8
- Book Value ₹ 92.8
- Dividend Yield 1.45 %
- ROCE 9.19 %
- ROE 6.91 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 47.8%
Cons
- The company has delivered a poor sales growth of 6.52% over past five years.
- Company has a low return on equity of 7.24% over last 3 years.
- Company has high debtors of 158 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 326 | 187 | 182 | 154 | 197 | 179 | 223 | 205 | 273 | 337 | 271 | 306 | |
| 294 | 162 | 164 | 145 | 174 | 156 | 193 | 189 | 245 | 301 | 232 | 258 | |
| Operating Profit | 32 | 25 | 17 | 9 | 23 | 23 | 30 | 15 | 28 | 37 | 39 | 48 |
| OPM % | 10% | 13% | 10% | 6% | 12% | 13% | 14% | 8% | 10% | 11% | 14% | 16% |
| 6 | -0 | 9 | 8 | 3 | 2 | 10 | 8 | 16 | 17 | 6 | 2 | |
| Interest | 13 | 10 | 10 | 7 | 5 | 6 | 4 | 3 | 3 | 4 | 4 | 4 |
| Depreciation | 10 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | 5 |
| Profit before tax | 15 | 11 | 13 | 7 | 17 | 16 | 33 | 16 | 37 | 45 | 36 | 40 |
| Tax % | 0% | 0% | 36% | 32% | 25% | 29% | 28% | 27% | 15% | 22% | 25% | 25% |
| 15 | 11 | 8 | 5 | 13 | 11 | 23 | 12 | 31 | 35 | 27 | 30 | |
| EPS in Rs | 3.77 | 2.64 | 1.97 | 1.09 | 3.00 | 2.59 | 5.43 | 2.44 | 6.48 | 7.19 | 5.57 | 6.30 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 55% | 123% | 46% | 42% | 54% | 48% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 7% |
| 3 Years: | 4% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 5% |
| 3 Years: | -1% |
| TTM: | 13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 2% |
| 3 Years: | 10% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 7% |
| 3 Years: | 7% |
| Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 41 | 43 | 43 | 43 | 43 | 43 | 43 | 48 | 48 | 48 | 48 | 48 |
| Reserves | 136 | 145 | 158 | 162 | 175 | 186 | 204 | 331 | 347 | 369 | 383 | 400 |
| 46 | 42 | 56 | 52 | 50 | 46 | 16 | 37 | 28 | 23 | 45 | 46 | |
| 51 | 49 | 54 | 42 | 50 | 52 | 61 | 48 | 82 | 71 | 70 | 112 | |
| Total Liabilities | 275 | 279 | 311 | 300 | 319 | 327 | 324 | 464 | 506 | 511 | 546 | 606 |
| 33 | 35 | 39 | 38 | 42 | 43 | 47 | 46 | 47 | 52 | 61 | 89 | |
| CWIP | 0 | 0 | 4 | 8 | 7 | 7 | 3 | 3 | 4 | 5 | 7 | 0 |
| Investments | 46 | 156 | 157 | 157 | 158 | 158 | 159 | 259 | 260 | 261 | 263 | 265 |
| 195 | 88 | 110 | 97 | 112 | 119 | 115 | 155 | 195 | 193 | 215 | 252 | |
| Total Assets | 275 | 279 | 311 | 300 | 319 | 327 | 324 | 464 | 506 | 511 | 546 | 606 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53 | 19 | 4 | 12 | 12 | 10 | 49 | -38 | 17 | 35 | 23 | 30 | |
| -10 | -4 | -9 | -2 | -4 | 1 | -9 | -100 | 10 | -6 | -15 | -30 | |
| -43 | -15 | 5 | -11 | -7 | -11 | -40 | 138 | -26 | -24 | 6 | -19 | |
| Net Cash Flow | -0 | 0 | -0 | -0 | -0 | 0 | 0 | -0 | 1 | 5 | 14 | -19 |
| Free Cash Flow | 41 | 13 | -8 | 7 | 6 | 5 | 44 | -41 | 11 | 24 | 6 | 4 |
| CFO/OP | 166% | 75% | 29% | 170% | 69% | 60% | 179% | -222% | 83% | 121% | 86% | 71% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 33 | 38 | 77 | 48 | 83 | 86 | 81 | 106 | 112 | 95 | 124 | 158 |
| Inventory Days | 24 | 90 | 84 | 119 | 78 | 149 | 73 | 119 | 98 | 78 | 129 | 141 |
| Days Payable | 63 | 114 | 120 | 115 | 101 | 114 | 106 | 85 | 128 | 82 | 108 | 162 |
| Cash Conversion Cycle | -6 | 14 | 41 | 52 | 60 | 121 | 48 | 139 | 82 | 91 | 145 | 137 |
| Working Capital Days | 124 | 41 | 46 | 49 | 59 | 59 | 64 | 129 | 116 | 104 | 114 | 109 |
| ROCE % | 11% | 10% | 10% | 5% | 9% | 8% | 14% | 6% | 9% | 11% | 9% | 9% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Gross Current Asset (GCA) Days Days |
|
||
| Export reach - Number of Nations Number |
|||
| Diagnostic Segment Customers (Kopran Labs) Number |
|||
| Employee Strength (Kopran Labs) Number |
|||
| Number of Diagnostic Machines (Kopran Labs) Number |
|||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
22 May - Secretarial compliance report for FY ended March 31, 2026; no non-compliances observed.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
21 May - Newspaper Advertisement for the Q4 Results FY 2025-26
- Announcement under Regulation 30 (LODR)-Investor Presentation 20 May
-
Board Meeting Outcome for Audited Financial Result For The Forth Quarter And Year Ended March 31, 2026.
19 May - Kopran approved FY26 audited results, recommended Rs.3 dividend, and appointed Namrata Somani as additional director.
-
Announcement under Regulation 30 (LODR)-Change in Management
18 May - Subsidiary KRLL approved 1:12 rights issue at ₹90 premium, raising ₹18.75 crore for working capital; appointed Chandresh Gandhi director.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Mar 2025TranscriptPPT
-
Feb 2025TranscriptPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT REC
-
Aug 2024TranscriptPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT
-
May 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
Business Verticals
1. API Vertical: WOS Kopran Research Laboratories operates the API vertical. [1] The co. undertakes development, manufacturing, and sale of diverse Active Pharmaceutical Ingredients and Advanced Intermediates. It is one of the leaders in Atenolol and has 26 commercialised products[2][3]